Page 2203 - Williams Hematology ( PDFDrive )

2178 Part XII: Hemostasis and Thrombosis Chapter 126: von Willebrand Disease 2179

83. Kaufmann JE, Oksche A, Wollheim CB, et al: Vasopressin-induced von Willebrand 115. Fretto LJ, Fowler WE, McCaslin DR, et al: Substructure of human von Willebrand fac-
factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest tor: Proteolysis by V8 and characterization of two functional domains. J Biol Chem
106:107–116, 2000. 261:15679–15689, 1986.
84. Sporn LA, Marder VJ, Wagner DD: Differing polarity of the constitutive and regu- 116. Fujimura Y, Titani K, Holland LZ, et al: A heparin-binding domain of human von
lated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 108: Willebrand factor. Characterization and localization to a tryptic fragment extending
1283–1289, 1989. from amino acid residue Val to Lys . J Biol Chem 262:1734–1739, 1987.
449
728
85. Ewenstein BM, Warhol MJ, Handin RI, Pober JS: Composition of the von Willebrand 117. Christophe O, Obert B, Meyer D, Girma J-P: The binding domain of von Willebrand
factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin,
vein endothelial cells. J Cell Biol 104:1423–1433, 1987. collagen and residues between amino acid residues Leu 512 and Lys 673. Blood 78:
86. Sporn LA, Marder VJ, Wagner DD: Inducible secretion of large, biologically potent von 2310–2317, 1991.
Willebrand factor multimers. Cell 46:185–190, 1986. 118. Yuan H, Deng N, Zhang S, et al: The unfolded von Willebrand factor response in blood-
87. Fernandez MF, Ginsberg MH, Ruggeri ZM, et al: Multimeric structure of platelet factor stream: The self-association perspective. J Hematol Oncol 5:65, 2012.
VIII/von Willebrand factor: The presence of larger multimers and their reassociation 119. Marchese P, Murata M, Mazzucato M, et al: Identification of three tyrosine residues of
with thrombin-stimulated platelets. Blood 60:1132–1138, 1982. glycoprotein IBα with distinct roles in von Willebrand factor and α-thrombin binding.
88. Wagner DD, Saffaripour S, Bonfanti R, et al: Induction of specific storage organelles by J Biol Chem 270:9571–9578, 1995.
von Willebrand factor propolypeptide. Cell 64:403–413, 1991. 120. Fujimura Y, Titani K, Holland LZ, et al: von Willebrand factor: A reduced and alkylated
89. Voorberg J, Fontijn R, Calafat J, et al: Biogenesis of von Willebrand factor-containing 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interact-
organelles in heterologous transfected CV-1 cells. EMBO J 12:749–758, 1993. ing with platelet glycoprotein Ib. J Biol Chem 261:381–385, 1986.
90. Journet AM, Saffaripour S, Cramer EM, et al: von Willebrand factor storage requires 121. Mohri H, Fujimura Y, Shima M, et al: Structure of the von Willebrand factor domain
intact prosequence cleavage site. Eur J Cell Biol 60:31–41, 1993. interacting with glycoprotein Ib. J Biol Chem 263:17901–17904, 1988.
91. Nachman RL, Jaffe EA: Subcellular platelet factor VIII antigen and von Willebrand 122. Nishio K, Anderson PJ, Zheng XL, Sadler JE: Binding of platelet glycoprotein Ibalpha
factor. J Exp Med 141:1101–1113, 1975. to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2
92. Bowie EJW, Solberg LA Jr, Fass DN, et al: Transplantation of normal bone marrow into by ADAMTS13. Proc Natl Acad Sci U S A 101:10578–10583, 2004.
a pig with severe von Willebrand’s disease. J Clin Invest 78:26–30, 1986. 123. Matsushita T, Sadler JE: Identification of amino acid residues essential for von Willebrand
93. Nichols TC, Samama CM, Bellinger DA, et al: Function of von Willebrand factor after factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of
crossed bone marrow transplantation between normal and von Willebrand disease the A1 domain of human von Willebrand factor. J Biol Chem 270:13406–13414, 1995.
pigs: Effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A 92:2455–2459, 124. Emsley J, Cruz M, Handin RI, Liddington R: Crystal structure of the von Willebrand
1995. factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol
94. André P, Brouland JP, Roussi J, et al: Role of plasma and platelet von Willebrand factor Chem 273:10396–10401, 1998.
in arterial thrombogenesis and hemostasis in the pig. Exp Hematol 26:620–626, 1998. 125. Chen J, Zhou H, Diacovo A, et al: Exploiting the kinetic interplay between GPIbα-
95. Bowen DJ, Collins PW: Insights into von Willebrand factor proteolysis: Clinical impli- VWF binding interfaces to regulate hemostasis and thrombosis. Blood 124:3799–3807,
cations. Br J Haematol 133:457–467, 2006. 2014.
96. Padilla A, Moake JL, Bernardo A, et al: P-selectin anchors newly released ultralarge von 126. Bienkowska J, Cruz M, Atiemo A, et al: The von Willebrand factor A3 domain does not
Willebrand factor multimers to the endothelial cell surface. Blood 103:2150–2156, 2004. contain a metal ion- dependent adhesion site motif. J Biol Chem 272:25162–25167, 1997.
97. Lopez JA, Dong JF: Shear stress and the role of high molecular weight von Willebrand 127. Huizinga EG, van der Plas RM, Kroon J, et al: Crystal structure of the A3 domain of
factor multimers in thrombus formation. Blood Coagul Fibrinolysis 16 Suppl 1:S11–S16, human von Willebrand factor: Implications for collagen binding. Structure 5:1147–
2005. 1156, 1997.
98. Dent JA, Berkowitz SD, Ware J, et al: Identification of a cleavage site directing the 128. Fukuda K, Doggett TA, Bankston LA, et al: Structural basis of von Willebrand factor
immunochemical detection of molecular abnormalities in type IIA von Willebrand activation by the snake toxin botrocetin. Structure 10:943–950, 2002.
factor. Proc Natl Acad Sci U S A 87:6306–6310, 1990. 129. Huizinga EG, Tsuji S, Romijn RA, et al: Structures of glycoprotein Ibalpha and its com-
99. Lankhof H, Damas C, Schiphorst ME, et al: von Willebrand factor without the A2 plex with von Willebrand factor A1 domain. Science 297:1176–1179, 2002.
domain is resistant to proteolysis. Thromb Haemost 77:1008–1013, 1997. 130. Hulstein JJ, Lenting PJ, de Laat B, et al: beta2-Glycoprotein I inhibits von Willebrand
100. Tsai H-M, Sussman II, Ginsburg D, et al: Proteolytic cleavage of recombinant type 2A factor dependent platelet adhesion and aggregation. Blood 110:1483–1491, 2007.
von Willebrand factor mutants R834W and R834Q: Inhibition by doxycycline and by 131. Scott JP, Montgomery RR, Retzinger GS: Dimeric ristocetin flocculates proteins, binds
monoclonal antibody VP-1. Blood 89:1954–1962, 1997. to platelets, and mediates von Willebrand factor-dependent agglutination of platelets.
101. Bowen DJ, Collins PW: An amino acid polymorphism in von Willebrand factor cor- J Biol Chem 266:8149–8155, 1991.
relates with increased susceptibility to proteolysis by ADAMTS13. Blood 103:941–947, 132. Berndt MC, Du XP, Booth WJ: Ristocetin-dependent reconstitution of binding of von
2004. Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex.
102. Johnsen J, Lopez JA: VWF secretion: What’s in a name? Blood 112:926–927, 2008. Biochemistry 27:633–640, 1988.
103. Reininger AJ: Function of von Willebrand factor in haemostasis and thrombosis. 133. Adachi T, Matsushita T, Dong Z, et al: Identification of amino acid residues essential for
Haemophilia 14 Suppl 5:11–26, 2008. heparin binding by the A1 domain of human von Willebrand factor. Biochem Biophys
104. Savage B, Almus-Jacobs F, Ruggeri ZM: Specific synergy of multiple substrate-receptor Res Commun 339:1178–1183, 2006.
interactions in platelet thrombus formation under flow. Cell 94:657–666, 1998. 134. Sobel M, McNeill PM, Carlson PL, et al: Heparin inhibition of von Willebrand fac-
105. Pendu R, Terraube V, Christophe OD, et al: P-selectin glycoprotein ligand 1 and tor-dependent platelet function in vitro and in vivo. J Clin Invest 87:1787–1793, 1991.
beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 135. Sobel M, Bird KE, Tyler-Cross R, et al: Heparins designed to specifically inhibit platelet
108:3746–3752, 2006. interactions with von Willebrand factor. Circulation 93:992–999, 1996.
106. Ruggeri ZM, Ware J, Ginsburg D: Von Willebrand factor, in Thrombosis and Hemor- 136. Nishio K, Anderson PJ, Zheng XL, Sadler JE: Binding of platelet glycoprotein Ibalpha
rhage, edited by J Loscalzo, AI Schafer, pp 246–265. Lippincott Williams & Wilkins, to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2
Philadelphia, 2003. by ADAMTS13. Proc Natl Acad Sci U S A 101:10578–10583, 2004.
107. Kalafatis M, Takahashi Y, Girma J-P, Meyer D: Localization of a collagen-interactive 137. Keuren JF, Baruch D, Legendre P, et al: von Willebrand factor C1C2 domain is involved
domain of human von Willebrand factor between amino acid residues Gly 911 and Glu in platelet adhesion to polymerized fibrin at high shear rate. Blood 103:1741–1746, 2004.
1365. Blood 70:1577–1583, 1987. 138. Keuren JF, Baruch D, Legendre P, et al: von Willebrand factor C1C2 domain is involved
108. Pareti FI, Niiya K, McPherson JM, Ruggeri ZM: Isolation and characterization of two in platelet adhesion to polymerized fibrin at high shear rate. Blood 103:1741–1746,
domains of human von Willebrand Factor that interact with fibrillar collagen types I 2004.
and III. J Biol Chem 262:13835–13841, 1987. 139. Vlot AJ, Koppelman SJ, van den Berg MH, et al: The affinity and stoichiometry of bind-
109. Takagi J, Sekiya F, Kasahara K, et al: Inhibition of platelet-collagen interaction by ing of human factor VIII to von Willebrand factor. Blood 85:3150–3157, 1995.
propolypeptide of von Willebrand factor. J Biol Chem 264:6017–6020, 1989. 140. Terraube V, O’Donnell JS, Jenkins PV: Factor VIII and von Willebrand factor interac-
110. Cruz MA, Yuan H, Lee JR, et al: Interaction of the von Willebrand factor (vWF) with tion: Biological, clinical and therapeutic importance. Haemophilia 16:3–13, 2010.
collagen. Localization of the primary collagen-binding site by analysis of recombinant 141. Cao W, Krishnaswamy S, Camire RM, et al: Factor VIII accelerates proteolytic cleavage
vWF A domain polypeptides. J Biol Chem 270:10822–10827, 1995. of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 105:7416–7421, 2008.
111. Lankhof H, Van Hoeij M, Schiphorst ME, et al: A3 domain is essential for interaction of 142. Foster PA, Fulcher CA, Marti T, et al: A major factor VIII binding domain resides
von Willebrand factor with collagen type III. Thromb Haemost 75:950–958, 1996. within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol
112. Rand JH, Patel ND, Schwartz E, et al: 150-kD von Willebrand factor binding protein Chem 262:8443–8446, 1987.
extracted from human vascular subendothelium is Type VI collagen. J Clin Invest 143. Yee A, Gildersleeve RD, Gu S, et al: A von Willebrand factor fragment containing the
88:253–259, 1991. D’D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood 124:
113. Rand JH, Wu X-X, Potter BJ, et al: Co-localization of von Willebrand factor and type VI 445–452, 2014.
collagen in human vascular subendothelium. Am J Pathol 142:843–850, 1993. 144. Bahou WF, Ginsburg D, Sikkink R, et al: A monoclonal antibody to von Willebrand
114. Mazzucato M, Spessotto P, Masotti A, et al: Identification of domains responsible for factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to
von Willebrand factor type VI collagen interaction mediating platelet adhesion under a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest
high flow. J Biol Chem 274:3033–3041, 1999. 84:56–61, 1989.

Kaushansky_chapter 126_p2163-2182.indd 2178 9/21/15 3:15 PM